fluxd
.news
Travere stock surges 44% on FDA approval for rare kidney disease · fluxd.news
fluxd
.news
LIVE
☽
Terms
Privacy
Cookies
☰
Back to Feed
Fintech
Travere stock surges 44% on FDA approval for rare kidney disease
Investing
·
April 14, 2026 at 11:18 AM
Original Source
Investing — www.investing.com
Share
Related in Fintech
OpenAI Expands Cybersecurity Program for AI Models
PYMNTS
Kraken crypto exchange files for IPO
PYMNTS
Ether.fi commits $3B to ETHGas futures
The Block
AI Models May Replace Software Incumbents
PYMNTS